CN110251412A - The preparation method of rhIL-12(p70) liposome and products thereof purposes - Google Patents
The preparation method of rhIL-12(p70) liposome and products thereof purposes Download PDFInfo
- Publication number
- CN110251412A CN110251412A CN201910570541.0A CN201910570541A CN110251412A CN 110251412 A CN110251412 A CN 110251412A CN 201910570541 A CN201910570541 A CN 201910570541A CN 110251412 A CN110251412 A CN 110251412A
- Authority
- CN
- China
- Prior art keywords
- rhil
- liposome
- preparation
- skin
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 8
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 8
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 42
- 239000006210 lotion Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000002953 phosphate buffered saline Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 7
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 238000012366 Fed-batch cultivation Methods 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 238000012784 weak cation exchange Methods 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 210000002615 epidermis Anatomy 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 3
- 230000003266 anti-allergic effect Effects 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 abstract description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 abstract description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 2
- 210000003764 chromatophore Anatomy 0.000 abstract description 2
- 108010051081 dopachrome isomerase Proteins 0.000 abstract description 2
- 238000001704 evaporation Methods 0.000 abstract description 2
- 230000008020 evaporation Effects 0.000 abstract description 2
- 231100000241 scar Toxicity 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002087 whitening effect Effects 0.000 abstract description 2
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 102000013462 Interleukin-12 Human genes 0.000 description 25
- 108010065805 Interleukin-12 Proteins 0.000 description 25
- 229940117681 interleukin-12 Drugs 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 238000000108 ultra-filtration Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000005538 encapsulation Methods 0.000 description 8
- 239000002884 skin cream Substances 0.000 description 8
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 229940040731 human interleukin-12 Drugs 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940047122 interleukins Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to technical field of liposome preparation, and in particular to the preparation method of rhIL-12(p70) liposome and the purposes for obtaining product.RhIL-12(p70) is added in the substances such as soybean lecithin and cholesterol and rhIL-12(p70) liposome is made by the present invention, rhIL-12(p70) after liposomal encapsulated is applied to comparatively fast enter deep skin in skin care item, it can be very good to play its antiallergy after skin absorbs, enhancing is immune, repair the effect of light injury, it is injury-free to maintain epidermis skin, tyrosinase related protein2 in basal layer of epidermis chromatophore is avoided or reduced to be activated, to reduce the melanin transfer generated after tyrosine activation to skin holostrome, the evaporation of moisture can also be reduced simultaneously, to reach whitening, moisturizing, it is wrinkle resistant, except the effect of scar, enter the good application prospect of high-end cosmetic display for rhIL-12(p70).
Description
Technical field
The invention belongs to technical field of liposome preparation, and in particular to the preparation of rhIL-12(p70) liposome
Method and the purposes for obtaining product, specifically 2 liposome of recombinant interleukin-1 is preparing the application in skin care item.
Background technique
Interleukin 12 (IL-12) is initially referred to as natural killer cells stimulating factor (NKSF) or cytotoxicity lymph
Cell maturation factors (CLMF), mainly by the monocyte activated and other kinds of cell (Dendritic Cells, B cell, in
Property granulocyte and horn cell) generate, be a kind of heterodimeric cytokine.IL-12 was found in 1992, found her
Begin to show that IL-12 has strong antiviral and anti-tumor effect, is known as the core that immune system exercises antiviral and antitumor
Regulatory factor is also known as the key protein matter of body natural immune system.
In recent years, discovery IL-12 has rush to the DNA damage of epidermal keratinocytes confluent monolayer cells caused by ultraviolet light (in involve long wave)
Into its repair.IL-12 mainly has the following aspects to the effect of skin: 1) IL-12 can reverse ultraviolet light and aging
Caused skin lesion, IL-12 reduce damage of the ultraviolet light to epidermal dna by activating the repair mechanism of DNA；2) purple
UV radiation can lead to the immunosuppressive action of skin；3) IL-12 Transdermal absorption passes through bright Han Shi to corium and subcutaneous tissue
The cell-mediated T lymphocyte that can activate corium promotes it to generate V- interferon, and V- interferon can inhibit fiber female thin
Born of the same parents' proliferation, inhibits proline hydroxylase required for collage synthesis, and collagen is prevented to generate.
In conclusion IL-12 has triple role to skin, it can by the prevention of activation DNA repair mechanism or mitigate
Epidermis caused by ultraviolet light or aging, DNA damage mitigate cutaneous immunisation caused by ultraviolet light or aging and inhibit, and prevent collagen fine
The hyperplasia of dimension promotes the hydrolysis of collagenous fibres, removes wrinkle, the function of scar to have.So as it can be seen that since IL-12 is tieed up
It is without damage to have protected normal epidermis, has avoided or reduced tyrosinase related protein2 in basal layer of epidermis chromatophore and is activated, to subtract
The melanin transfer generated after few tyrosine activation is to skin holostrome, to play the whitening function of skin, meanwhile, it can be with
The moisture evaporation for reducing skin, avoids or reduces the apoptosis of keratinocyte, reduces the secretion of elastase, so that elasticity is hard
Albumen maintains normal condition, increases skin elasticity, reduces the appearance of wrinkle.Therefore, more and more IL-12 are applied to
In cosmetics.
Patent document CN102641217A discloses a kind of application of interleukin 12 in cosmetics, is intended to mention
Skin immune function controlling, antiallergy, the cosmetic additive agent for repairing skin injury can be enhanced for one kind.However IL-12 is molecular weight
For the macromolecular substances of 70KD, directly adding use can not be such that skin absorbs, and be unable to reach due effect.
Summary of the invention
In order to overcome defect existing in the prior art, the purpose of the present invention is to provide a kind of combining human interleukins
The preparation method of plain -12 liposomes, encapsulates rhIL-12(p70) using liposome, and protection recombined human is white thin
Born of the same parents interleukin -12 prevent it from interfering with each other with other substances in formula, and avoid the contact with extraneous factor, reduce by wind
A possibility that dry, can also avoid the degradation of rhIL-12(p70) and go bad, improve the stability of itself, and drop
Its low irritation to skin.
The present invention provides a kind of preparation methods of rhIL-12(p70) liposome, comprising the following steps:
The Chinese hamster ovary celI for stablizing expression rhIL-12 is carried out fed-batch cultivation through bioreactor by S1, is taken in culture
Clear liquid is chromatographed through weak cation exchange respectively, and heparin affinity chromatography separation obtains rhIL-12；
S2 takes soybean lecithin, cholesterol to be dissolved in chloroform, is ultrasonically treated 8~12min, the ultrasound input power
It is 40%, obtains mixed liquor I；
Ether and chloroform are added into the mixed liquor I that step S2 is obtained by S3, and the PBS buffer solution that pH is 6.8 is added dropwise, and surpass
To not stratified, the ultrasound input power is 40% for sonication, obtains w/o type lotion；
The w/o type lotion that step S3 is obtained is evaporated under reduced pressure S4 under the conditions of 50 DEG C of waters bath with thermostatic control, obtains O/W type lotion；
The O/W type lotion that S5 obtains step S4 carries out high-pressure homogeneous 15~25min, and every 5min is 1 circulation, filters,
The additive amount that rhIL-12 described in the rhIL-12 that step S1 is collected is added is 70-100ug/ml,
It is subsequently added into protein protectant, 18~22min is incubated under conditions of 37 DEG C, excipient mixing packing is added, it is pre- in -40 DEG C
Freeze 2h, be freeze-dried under conditions of vacuumizing for 24 hours, in 4 DEG C save to get.
Further, the solid-to-liquid ratio of soybean lecithin, cholesterol and chloroform is 4g:1g in the step S2:
200ml。
Further, the volume ratio of ether, chloroform and PBS buffer solution is 3:1:2 in the step S3.
Further, the volume ratio of chloroform and the chloroform in step S3 is 2:1 in the step S2.
Further, the concentration of PBS buffer solution is 0.02mol/L in the step S3.
Further, the pressure of the step S5 mesohigh homogeneous is 10000~15000Pa.
Further, the filtering in the step S5 be pass sequentially through 1.0um, 0.6um, 0.45um and 0.22um filter membrane into
Row filtering.
Further, the protein protectant in the step S5 is that the bovine serum albumin(BSA) that mass concentration is 0.1% is molten
The volume ratio of liquid, the protein protectant and rhIL-12(p70) is 10:1.
Further, the excipient in the step S5 is (1.5~2) by trehalose and glyceroglycolipid in mass ratio: 1 group
At the mass ratio of the excipient and rhIL-12(p70) is 2:1.
In addition, the present invention also provides the preparation methods of the rhIL-12(p70) liposome to be prepared
RhIL-12(p70) liposome preparing the purposes in skin care item.
RhIL-12(p70) provided by the invention is by the recombination of expressing cho cell fermentation supernatant purification
HIL-12, host cell are preferably Chinese hamster ovary cell CHO-S.Recombined human produced by the present invention is white thin
The average grain diameter of -12 liposome of born of the same parents' interleukin is 100~300nm, preferably 200nm.The rhIL-12(p70) liposome can
The form for thinking freeze-drying prods, further includes mannitol.
The preparation method of rhIL-12(p70) liposome provided by the invention is the load using lipid as IL-12
The transdermal absorption factor of IL-12 can be improved by the IL-12 of the encapsulating of liposome for body, while can also enhance the anti-mistake of IL-12
Quick, enhancing is immunized, repairs the effect of light injury, extends action time, reduces the additive amount of IL-12 in skin care item.
In short, compared with prior art, the preparation method of rhIL-12(p70) liposome provided by the invention has
There is following advantage:
(1) preparation method of rhIL-12(p70) liposome provided by the invention is using liposome to recombination
HIL-12 is encapsulated, and rhIL-12(p70) is protected, and prevents itself and other substances in skin care item formula
Interfere with each other, and avoid the contact with extraneous factor, reduce a possibility that being air cured, recombinant human leucocyte can also be avoided
The degradation of interleukin -12 and rotten, improves the stability of itself, and reduce its irritation to skin.
(2) recombinant human leucocyte made from the preparation method of rhIL-12(p70) liposome provided by the invention
The transdermal absorption factor of -12 liposome of interleukin is high, can greatly promote the absorption and utilization of skin, more advantageous combining human interleukins
Element -12 plays antiallergy, and enhancing is immune, repairs the effect of light injury.
Detailed description of the invention:
Fig. 1 is the transdermal absorption factor figure of rhIL-12(p70) liposome.
Specific embodiment
The present invention is further described below by way of specific embodiment, the present invention is not limited only to following embodiment.In this hair
In bright range or the contents of the present invention are not being departed from, in spirit and scope, the change that carries out to the present invention is combined or replaced
It changes, will be apparent to the person skilled in the art, and be included within the scope of the present invention.Makeup of the invention
Product ingredient is conventional commercially available ingredient.
Embodiment 1, a kind of preparation method of rhIL-12(p70) liposome
The Chinese hamster ovary celI for stablizing expression rhIL-12 through 5L bioreactor fed-batch cultivation, is taken culture supernatant by S1
Liquid is chromatographed through weak cation exchange respectively, and heparin affinity chromatography separation obtains rhIL-12；
S2 takes soybean lecithin, cholesterol to be dissolved in chloroform, the soybean lecithin, cholesterol and chloroform
Solid-to-liquid ratio is 4g:1g:200ml, is ultrasonically treated 8~12min, and the ultrasound input power is 40%, obtains mixed liquor I；
Ether and chloroform are added into the mixed liquor I that step S2 is obtained by S3, and it is 6.8 that pH, which is added dropwise, and concentration is
The PBS buffer solution of 0.02mol/L, the volume ratio of the ether, chloroform and PBS buffer solution are 3:1:2, in the step S2
The volume ratio of chloroform in chloroform and step S3 is 2:1, and to not stratified, the ultrasound input power is ultrasonic treatment
40%, obtain w/o type lotion；
The w/o type lotion that step S3 is obtained is evaporated under reduced pressure S4 under the conditions of 50 DEG C of waters bath with thermostatic control, obtains O/W type lotion；
The O/W type lotion that step S4 is obtained is carried out high-pressure homogeneous 15 under conditions of pressure is 10000~15000Pa by S5
~25min, every 5min are 1 circulation, pass sequentially through 1.0um, 0.6um, 0.45um and 0.22um filter membrane and are filtered, and step is added
The additive amount of rhIL-12 described in the rhIL-12 that rapid S1 is collected is 70-100ug/ml, then plus
Entering mass concentration is 0.1% bovine serum albumin solution, the volume of the protein protectant and rhIL-12(p70)
Than for 10:1, excipient mixing packing is added in 18~22min of incubation under conditions of 37 DEG C, and the excipient and recombined human are white
The mass ratio of cytokine -12 is 2:1, and the excipient is (1.5~2) by trehalose and glyceroglycolipid in mass ratio: 1 group
At, in -40 DEG C of pre-freeze 2h, be freeze-dried under vacuum-pumping conditions for 24 hours, in 4 DEG C save to get.
Embodiment 2, a kind of preparation method of rhIL-12(p70) liposome
The Chinese hamster ovary celI for stablizing expression rhIL-12 through 5L bioreactor fed-batch cultivation, is taken culture supernatant by S1
Liquid is chromatographed through weak cation exchange respectively, and heparin affinity chromatography separation obtains rhIL-12；
S2 takes 1.0g soybean lecithin, 0.25g cholesterol to be dissolved in 50ml chloroform, is ultrasonically treated 10min, described super
Vocal input power is 40%, obtains mixed liquor I；
75ml ether and 25ml chloroform are added into the mixed liquor I that step S2 is obtained by S3, and it is 6.8 that pH, which is added dropwise, concentration
For the PBS buffer solution of 0.02mol/L, for ultrasonic treatment to not stratified, the ultrasound input power is 40%, obtains w/o type lotion；
The w/o type lotion that step S3 is obtained is evaporated under reduced pressure S4 under the conditions of 50 DEG C of waters bath with thermostatic control, obtains O/W type lotion；
The O/W type lotion that S5 obtains step S4 is that 12000Pa carries out high-pressure homogeneous 20min in pressure, and every 5min is 1
Circulation, passes sequentially through 1.0um, 0.6um, 0.45um and 0.22um filter membrane and is filtered, and the recombination that step S1 is collected is added
Human Interleukin-12, the additive amount of the rhIL-12 are 800ug/ml, and being subsequently added into mass concentration is 0.1% ox blood
The volume ratio of pure protein solution, the protein protectant and rhIL-12(p70) is 10:1, in 37 DEG C of condition
Lower incubation 20min is added excipient mixing and dispenses, and the mass ratio of the excipient and rhIL-12(p70) is 2:1,
The excipient is made of in mass ratio for 1.8:1 trehalose with glyceroglycolipid, in -40 DEG C of pre-freeze 2h, under vacuum-pumping conditions
Freeze-drying for 24 hours, in 4 DEG C save to get.
Embodiment 3, a kind of skin cream containing rhIL-12(p70) liposome
The formula of the skin cream is as shown in table 1:
A kind of skin cream containing rhIL-12(p70) liposome of table 1
By the formula of table 1: respectively by A phase and B heat phase to 80 DEG C, in the case where starting homogeneous stirring, A being added to B phase
In, after emulsification uniformly, C phase is added after reducing temperature, is cooled to 40 DEG C of addition D phases, discharges after mixing evenly.
Embodiment 4, a kind of facial mask liquid containing rhIL-12(p70) liposome
The formula of the facial mask liquid is as shown in table 2:
A kind of facial mask liquid containing rhIL-12(p70) liposome of table 2
By the formula of table 2: being first pre-mixed B phase, be heated to 80 DEG C, adjust pH with triethanolamine, be gradually added preheating
A phase constituent, stir evenly, after cooling, gradually add C phase constituent, stir evenly.
The stability test of test example one, rhIL-12(p70) liposome
1, test material:
The rhIL-12(p70) liposome that embodiment 2 is prepared.
2, test method:
2.1, study on the stability:
The recombinant human interleukin 12 liposome that embodiment 2 is prepared is dissolved in water, by rhIL-12 aqueous solution in temperature
It spends at 4,25,30,40 DEG C, closed placement under the conditions of relative humidity 75%.0 after placement, 1,2, March.It is surveyed respectively with Elisa method
The content of recombinant human interleukin-12 in liposome and aqueous solution is determined, with combining human interleukins in liposome at 0 month and aqueous solution
Element -12 is 100%, other each time rhIL-12(p70) contents are made comparisons therewith, obtain combining human interleukins
Plain -12 contents change over time percentage.
Detailed process is as follows for sandwich ELISA method:
(1) Human IL-12 p70 Antibo is diluted with coating buffer (carbonate buffer solution of pH9.6,0.1M)
(CatalogNumber:MAB611-500) is used for coated antibody to 2 μ g/ml, is added in 96 hole elisa Plates with 100 holes μ l/, 4 DEG C
Overnight.
(2) detain dry coating buffer, with PBST (phosphate buffer+polysorbas20 of pH7.4,0.1M, polysorbas20 it is final concentration of
Percent by volume 0.05%) it is added in 96 hole elisa Plates with 300 holes μ l/, board-washing 1 time, each 3min.
(3) by the standard items diluted (Recombinant Human IL-12 standard items be purchased from R&D company, article No.:
219-IL) with 2 times of gradient dilutions of the PBST of the 1%BSA containing mass volume ratio, dilution range 0.12ng/L-7.8ng/L；It is to be measured
Sample dilutes 10000 times with the PBST of the 1%BSA containing mass volume ratio, is added in plate with 100 holes μ l/, and 37 DEG C are placed 1 hour.
(4) with PBST cleaning solution with 300 hole μ l/ board-washing 3 times, each 3min.
(5) with the secondary antibody diluent of the 5%BSA containing mass volume ratio (2g BSA+40ml PBST) by biotin labeling
Human IL-12Biotinylated Antibody (Catalog#BAF219) is diluted to 0.1 μ g/ml, is added to 100 holes μ l/
In plate, 37 DEG C are placed 1 hour.
(6) dry microwell plate is detained, 1x PBST is added, 300 holes μ l/ stand 3min, wash 5 times.
(7) be added HRP label Streptavidin (1:1000 dilution: Solarbio | article No.: S9170), 100 holes μ l/,
It is diluted with 1x PBS or 1xPBST.37 DEG C of incubation 45min.
(8) dry microwell plate is detained, washing lotion is added, 300 holes μ l/ stand 3min, wash 5 times.
(9) TMB chromogenic substrate (green skies P0209) is added, 100 holes μ l/ are protected from light, and are incubated at room temperature 5-30min.
(10) 20%H is added2SO4It terminates, 100 holes μ l/ are normal from indigo plant flavescence, please be light if greening or color change are uneven
Sheet frame is hit in tapping, is mixed well.
(11) OD450, OD630 are detected in 30min, OD value=OD450-OD630 does standard curve by standard items, counts
Calculate the content of rhIL-12 in sample.Each sample does 3 multiple holes when detection, is averaged.
2.2, the measurement of liposome encapsulation:
It is centrifuged using ultrafiltration, after liposome is separated with free drug, free drug is contained with indirect method
Amount is measured.This test of separation method selection ultrafiltration of liposome is divided rhIL-12 liposome and free rhIL-12
From.
The pre-treatment of ultra-filtration centrifuge tube takes ultra-filtration centrifuge tube capacity for 4ml, molecular cut off 100KD, ultrapure at 4 DEG C
Soaked overnight in water.Ultrapure water used when immersion is discarded, fresh ultrapure water is added in ultra-filtration centrifuge tube and is placed in high speed
Washing is centrifuged in centrifuge, is centrifuged 15min in 3000rpm.It is discarded after centrifugation ultrapure in ultra-filtration centrifuge tube
Simultaneously fresh ultrapure water is added in water, this process is repeated 3 times, spare.
The ultrafiltration of rhIL-12 liposome is centrifugated, and is taken the liposome of 300ul rhIL-12, is diluted to 3.0ml with PBS
It is added in ultra-filtration centrifuge tube afterwards.It after sample stable equilibrium, is placed in supercentrifuge and is centrifuged, be centrifuged in 3000rpm
20min retains lower layer's ultrafiltrate, spare.
Penetration ration of the rhIL-12 to ultrafiltration membrane: precision measures the rhIL-12 reference solution that concentration is 50ug/ml and is
Each 4 parts of 0.15ml, 0.50ml, 1.5ml, distilled water is added in ultra-filtration centrifuge tube after being diluted to 3.0ml.It is centrifuged in 3000rpm
20min retains lower layer's ultrafiltrate, is measured according to the above method to rhIL-12 content.
The amount of rhIL-12/addition rhIL-12 Zong Liang ╳ 100% in Penetration ration (%)=ultrafiltrate.
The rhIL-12 of various concentration is about (93.05 ± 5.33) % to the average Penetration ration of ultrafiltration membrane after measured, shows to put down
It is the super of 100KD that the recombined human rhIL-12 protein molecular that equal relative molecular weight is 70KD, which most can penetrate molecule interception,
Filter membrane.
2.3, the encapsulation rate of ultrafiltration measurement liposome:
Ultrafiltrate after taking liposome ultrafiltration to be centrifugated, measures the content (C trip) of rhIL-12, to dissociate rhIL-12's
Content separately takes liposomal samples 300ul, and chloroform 900ul is added, and shake well is uniformly mixed, and is centrifuged in 12000rpm
20min takes supernatant and is diluted with distilled water, measures the content (C is total) of rhIL-12, the total content of rhIL-12, by following public affairs
Formula calculates the encapsulation rate of liposome:
Encapsulation rate (EN)=(total-C trip of C)/C Zong ╳ 100%
Physical stability, this test are measured physical stability parameter using centrifugation-spectrophotometry.Precision is inhaled
RhIL-12 liposomal samples 1mL is taken, 3500rpm/min in centrifuge tube is set and is centrifuged 10min, liposome and centrifugation before taking centrifugation
Each 0.3mL of upper liquid afterwards, respectively plus PBS (pH6.8) is diluted to 5.0mL, using PBS as blank, measures it at Yu Bochang 500nm
Absorbance (absorbance value that liposome centrifugation front and back measures is respectively A0, A), computational stability parameter value.KE=(A0-A)/A0
× 100% value is smaller, illustrates that liposome is more stable.
2.4, Determination of biological activity:
The natural killer cells NK92mi cell of the people Chlorambucil patient applied flexibly is surveyed purchased from Chinese food
Drug assay research institute: NK-92mi uses culture medium A lpha MEM supplemented with 12%fetal bovine
Serum, 12%horse serum, 1%penicillin/streptomycin, 0.2mM inositol, 0.02mM folic
Acid, and 0.1mM 2-mercaptoethanol are cultivated spare.
(1) NK92mi cell grows to logarithmic growth phase, and piping and druming is uniformly dispersed, and is resuspended in fresh complete medium, adjusts
Whole cell density is to 1 × 106A cell/ml is inoculated with 96 porocyte culture plates.It is inoculated with 100 hole μ l/ of volume.
(2) 37 DEG C, 5%CO2, it is incubated overnight under conditions of saturated humidity.
(3) 4 times of gradient dilution standard items and sample are pressed with complete medium dilution.50 holes μ l/ are added in 96 orifice plates, and 37 DEG C
It is incubated for culture.
(4) with the IFN-Y's in eBiosciences88-7317 kit method detection culture supernatant after 24-48 hours
Content.
(5) 4 parametric methods are used, are mapped with the logarithm of IL-12 concentration to sample light absorption value, according to the ED50 of each test sample
(test sample concentration when i.e. IFN-Y content is maximum concentration half), is calculated as follows the potency of sample to be tested.
The ED50 of sample to be tested potency (IU/MG)=standard items potency X standard items ED50/ test specimen
The above-mentioned rhIL-12 liposome prepared by embodiment 2 is placed at 4,25,30,40 DEG C of temperature respectively, is relatively wet
Closed placement under the conditions of degree 75%.0 after placement, investigate within 1,3,5,10,30,60,90 days its encapsulation rate, physical stability, activity.
3, test result:
3.1, study on the stability result: the result shows that, under the conditions of 40 DEG C of temperature, relative humidity 75%, place 3 months,
Changes of contents of the recombinant human interleukin 12 in liposome complex is little, and in recombinant human interleukin 12 aqueous solution
Middle content reduces, it was demonstrated that after liposomal encapsulated, hence it is evident that improve the stability of recombinant human interleukin 12.
3.2, the measurement result of liposome encapsulation it is as shown in table 3.
3.3, the measurement result of the encapsulation rate of liposome is as shown in table 4.
3.4, the results are shown in Table 5 for Determination of biological activity.
The encapsulation rate (%) of rhIL-12 liposome is investigated under 3 different condition of table
| 0 day | 1 day | 3 days | 5 days | 10 days | 30 days | 60 days | 90 days | |
| 4℃ | 85.20 | 84.00 | 81.45 | 78.25 | 78.93 | 74.65 | 69.25 | 64.07 |
| 25℃ | 85.20 | 85.15 | 78.83 | 74.85 | 73.22 | 64.76 | 57.38 | 45.45 |
| 30℃ | 85.20 | 84.25 | 76.05 | 69.83 | 63.22 | 41.35 | 29.95 | 21.88 |
| 40℃ | 85.20 | 85.05 | 72.35 | 66.92 | 60.13 | 37.55 | 23.15 | 18.76 |
The physical stability of rhIL-12 liposome investigates (%) under 4 different condition of table
| 0 day | 1 day | 3 days | 5 days | 10 days | 30 days | 60 days | 90 days | |
| 4℃ | 1.08 | 1.55 | 1.52 | 2.34 | 2.61 | 3.88 | 3.56 | 3.68 |
| 25℃ | 1.08 | 1.23 | 1.13 | 1.46 | 1.53 | 2.01 | 6.12 | 6.68 |
| 30℃ | 1.08 | 1.43 | 2.65 | 4.58 | 11.88 | 24.33 | 32.66 | 39.35 |
| 40℃ | 1.08 | 2.05 | 3.55 | 9.98 | 10.76 | 25.12 | 35.02 | 43.12 |
The biological activity (× 10 of rhIL-12 liposome under 5 different condition of table5IU/ml)
| 0 day | 1 day | 3 days | 5 days | 10 days | 30 days | 60 days | 90 days | |
| 4℃ | 4.22 | 4.05 | 3.94 | 4.11 | 3.78 | 3.58 | 3.88 | 3.78 |
| 25℃ | 4.22 | 4.68 | 3.78 | 3.98 | 3.84 | 3.35 | 3.12 | 3.05 |
| 30℃ | 4.22 | 3.45 | 3.23 | 2.89 | 2.55 | 1.88 | 1.63 | 1.14 |
| 40℃ | 4.22 | 3.95 | 3.22 | 2.65 | 2.73 | 1.18 | 1.26 | 0.98 |
The percutaneous absorbability of test example two, rhIL-12(p70) liposome
1, test material:
The rhIL-12(p70) liposome that embodiment 2 is prepared.
2, test method:
2.1, prepared by skin: 12 Wistar female mices, and mouse is broken after neck puts to death, belly wool is cut off, separates abdomen skin
Skin removes subcutaneous fascia and fat, puts -20 DEG C of ice of people after being wrapped up with aluminium foil until without muddiness with physiological saline repeated flushing
Case refrigeration is spare.
2.2, Transdermal absorption measures: same mouse mouse skin being cut into 2 pieces of suitable size, infuses human physiology salt in receiving chamber
Water receiving liquid 6.87mL, mouse skin is fixed between the diffuser casing and receiving chamber of skin permeation test in vitro device, and stratum corneum side is to expansion
Room is dissipated, liquid level is contacted with skin inner layer completely, is respectively charged into the combining human interleukins of equivalent in two diffusion cells respectively
The rhIL-12(p70) liposome that plain 12 aqueous solutions and embodiment 2 are prepared, sample-adding start to count after balancing 30min
When, electromagnetic constant-temperature blender is opened, 37 DEG C ± 2 DEG C of temperature, the stirring of 100r/min constant speed takes in reception tank respectively at 1-12h
Sample 0.3mL, while adding 0.3mL physiological saline and draining bubble.It is saturating that different time in two reception tanks is measured using ELISA method
Protein content in skin liquid calculates skin permeation rate；Using relative molecular weight in high performance liquid chromatography measurement each sample.
The calculating of skin permeation rate: skin permeation rate=(CnVn+ Σ CkVk)/m × 100%
In formula: the protein concentration (mg/mL) that n-th of sample point of Cn-measures；All samplings before n-th of sample point of Ck-
The corresponding protein concentration (mg/mL) measured of point；Ck-receiving liquid volume (mL)；All sample point phases before n-th of sample point
Corresponding sample volume (mL)；The quality (mg) of protein in m-raw sample.
3, test result:
Test result is as shown in Figure 1.
The prevention and repair of test example three, the skin care item of liposome containing rhIL-12(p70) to light injury
1, test material:
Skin cream containing rhIL-12(p70) liposome made from embodiment 3.
2, test method:
Volunteer men and women each 24 for choosing health, are randomly divided into 3 groups, respectively control group, comparative example group and examination
Test group, in which: control group is physiological saline group, and comparative example group is by the recombinant human interleukin-in the skin cream of embodiment 3
12 liposomes replace with skin cream made from rhIL-12(p70), and test group is to contain recombined human made from embodiment 3
The skin cream of interleukin 12 liposome.Subject takes position of leaning forward, and takes back normal skin region, and cleaning skin is dried,
Three regions, each region 4cm × 4cm are divided into, luminous intensity is tested in xenon lamp preheating after five minutes, and light source generates 280~400nM
Ultraviolet light, after optical filter, light source output is stablized, and light is uniform.Physiological saline, the comparative example of control group are drawn with cotton swab
The skin cream about 1g of group and test group is applied to respectively in corresponding region, is spontaneously dried, and after half an hour, subject receives artificial mould
Quasi- solar attachment Solar Light 601 irradiates, exposure dose 80mJ.cm-2.Examination is observed after 3 times repeatedly, 24 hours and 72 hours
Test result.
3, test result:
After 24 hours, the erythema rate in control group region is 76.2%, and the erythema rate in comparative example group region is 50.4%, test
The erythema rate in group region is 28.5%, and erythema is light.After 72 hours, part subject's control group region and comparative example group region
The appearance desquamation of skin, and the intact no furfur phenomenon of test group area skin.
Claims (10)
1. a kind of preparation method of rhIL-12(p70) liposome, which comprises the following steps:
The Chinese hamster ovary celI for stablizing expression rhIL-12 is carried out fed-batch cultivation through bioreactor by S1, takes culture supernatant
It is chromatographed respectively through weak cation exchange, heparin affinity chromatography separation obtains rhIL-12；
S2 takes soybean lecithin, cholesterol to be dissolved in chloroform, is ultrasonically treated 8~12min, obtains mixed liquor I；
Ether and chloroform are added into the mixed liquor I that step S2 is obtained by S3, and pH is added dropwise for 6.8 PBS buffer solution, at ultrasound
Reason obtains w/o type lotion to not stratified；
The w/o type lotion that step S3 is obtained is evaporated under reduced pressure S4 under the conditions of 50 DEG C of waters bath with thermostatic control, obtains O/W type lotion；
The O/W type lotion that S5 obtains step S4 carries out high-pressure homogeneous 15~25min, and every 5min is 1 circulation, filters, is added
The additive amount of rhIL-12 described in the rhIL-12 that step S1 is collected is 70-100ug/ml, then
Protein protectant is added, 18~22min is incubated under conditions of 37 DEG C, excipient mixing packing is added, in -40 DEG C of pre-freezes
2h, be freeze-dried under conditions of vacuumizing for 24 hours, in 4 DEG C save to get.
2. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
The solid-to-liquid ratio of soybean lecithin, cholesterol and chloroform is 4g:1g:200ml in rapid S2.
3. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
The volume ratio of ether, chloroform and PBS buffer solution is 3:1:2 in rapid S3.
4. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
The volume ratio of chloroform and the chloroform in step S3 is 2:1 in rapid S2.
5. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
The concentration of PBS buffer solution is 0.02mol/L in rapid S3.
6. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
The pressure of rapid S5 mesohigh homogeneous is 10000~15000Pa.
7. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
Filtering in rapid S5 is to pass sequentially through 1.0um, 0.6um, 0.45um and 0.22um filter membrane to be filtered.
8. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
Protein protectant in rapid S5 is the bovine serum albumin solution that mass concentration is 0.1%.
9. the preparation method of rhIL-12(p70) liposome as described in claim 1, which is characterized in that the step
Suddenly the excipient in S5 is (1.5~2) by trehalose and glyceroglycolipid in mass ratio: 1 forms.
10. the preparation method of the rhIL-12(p70) liposome as described in claim 1~9 is any is prepared
RhIL-12(p70) liposome is preparing the purposes in skin care item.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910570541.0A CN110251412A (en) | 2019-06-27 | 2019-06-27 | The preparation method of rhIL-12(p70) liposome and products thereof purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910570541.0A CN110251412A (en) | 2019-06-27 | 2019-06-27 | The preparation method of rhIL-12(p70) liposome and products thereof purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110251412A true CN110251412A (en) | 2019-09-20 |
Family
ID=67922648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910570541.0A Pending CN110251412A (en) | 2019-06-27 | 2019-06-27 | The preparation method of rhIL-12(p70) liposome and products thereof purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110251412A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476586A (en) * | 2021-07-08 | 2021-10-08 | 神究富硒农业发展(山东)有限公司 | Preparation method of selenium-rich cell repair liquid |
| CN117959250A (en) * | 2024-03-27 | 2024-05-03 | 长春生物制品研究所有限责任公司 | Recombinant human interleukin-1 receptor antagonist injection |
| CN118001176A (en) * | 2024-04-09 | 2024-05-10 | 山东泉港药业有限公司 | Application of recombinant human interleukin 2 (I) |
| CN118078673A (en) * | 2024-04-11 | 2024-05-28 | 山东泉港药业有限公司 | Application of recombinant human interleukin 2 (I) in anti-wrinkle compact product |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926770A (en) * | 2009-06-25 | 2010-12-29 | 浙江海正药业股份有限公司 | Drug-loaded liposome and preparation method thereof |
| CN102641217A (en) * | 2012-05-07 | 2012-08-22 | 广州市恺泰生物科技有限公司 | Application of interleukin-12 in facial beautifiers |
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| CN107375906A (en) * | 2017-07-28 | 2017-11-24 | 广东科玮生物技术股份有限公司 | A kind of scar repair agent and preparation method thereof |
-
2019
- 2019-06-27 CN CN201910570541.0A patent/CN110251412A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926770A (en) * | 2009-06-25 | 2010-12-29 | 浙江海正药业股份有限公司 | Drug-loaded liposome and preparation method thereof |
| CN102641217A (en) * | 2012-05-07 | 2012-08-22 | 广州市恺泰生物科技有限公司 | Application of interleukin-12 in facial beautifiers |
| CN106466299A (en) * | 2015-08-19 | 2017-03-01 | 上海本素医药科技有限公司 | Blank liposome with ginsenoside as membrane material, its preparation method and application |
| CN107375906A (en) * | 2017-07-28 | 2017-11-24 | 广东科玮生物技术股份有限公司 | A kind of scar repair agent and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 滕跃等: "重组人酸性成纤维细胞生长因子脂质体的制备及其物理稳定性评价", 《吉林大学学报医学版》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476586A (en) * | 2021-07-08 | 2021-10-08 | 神究富硒农业发展(山东)有限公司 | Preparation method of selenium-rich cell repair liquid |
| CN113476586B (en) * | 2021-07-08 | 2024-05-10 | 神究富硒农业发展(山东)有限公司 | Preparation method of selenium-enriched cell repair liquid |
| CN117959250A (en) * | 2024-03-27 | 2024-05-03 | 长春生物制品研究所有限责任公司 | Recombinant human interleukin-1 receptor antagonist injection |
| CN118001176A (en) * | 2024-04-09 | 2024-05-10 | 山东泉港药业有限公司 | Application of recombinant human interleukin 2 (I) |
| CN118001176B (en) * | 2024-04-09 | 2024-07-16 | 山东泉港药业有限公司 | Application of recombinant human interleukin-2-I |
| CN118078673A (en) * | 2024-04-11 | 2024-05-28 | 山东泉港药业有限公司 | Application of recombinant human interleukin 2 (I) in anti-wrinkle compact product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110251412A (en) | The preparation method of rhIL-12(p70) liposome and products thereof purposes | |
| CN105055285B (en) | A kind of skin-nourishing liquid and preparation method thereof | |
| CN104644461B (en) | Application of the compound with promotion collagen synthesis activity in anti-aging cosmetics | |
| CN107184417A (en) | Soluble microneedle patch and preparation method thereof | |
| CN102421412B (en) | Composition containing chamaecyparis obtusa polysaccharides to be externally applied to skin | |
| CN110151678A (en) | It is a kind of for improving the composition and cosmetics comprising source of human stem cell excretion body of wrinkle | |
| CN103976908B (en) | A kind ofly be rich in the composition of plant extracts of plant polypeptide and the application in cosmetics thereof | |
| CN105997835B (en) | A kind of preparation method and products thereof of the biological beauty raw material in immunocyte source | |
| CN108998225B (en) | Preparation method and application of peony seed oil | |
| CN108498364A (en) | Liquid crystal cutaneous permeable agent and its preparation and the application in anti-aging cosmetics | |
| CN113855597A (en) | Antioxidant, anti-inflammatory and soothing repair composition, preparation method and application thereof | |
| CN107744481B (en) | A kind of moisturizing is releived spraying and preparation method thereof | |
| US11273114B2 (en) | Compound additive having biological activation function, preparation method therefor and use thereof | |
| CN109248135A (en) | A kind of sheen highlights, the external-use skin care of concealing moisturizing combination and preparation method thereof | |
| CN108721137A (en) | A kind of freeze-dried powder for repairing skin | |
| CN108703931A (en) | A kind of composition and preparation method thereof with moisture-keeping function | |
| CN101658479B (en) | Application of nanometer pearl powder in cosmetic skin care products | |
| CN107334739B (en) | Fibroblast growth factor liposome freeze-dried powder for preventing and treating alopecia and preparation method thereof | |
| CN105853341A (en) | Anti-aging skincare product containing epidermal stem cell secretin and preparation method of anti-aging skincare product | |
| CN105310972A (en) | Anti-wrinkle skin care product | |
| CN1660048A (en) | Frost-like powder possessing effects of beautification and nourishing face | |
| CN111135118A (en) | Anti-aging polypeptide composition | |
| CN101785752A (en) | Composite nanoemulsion used for epidermis repair and preparation method thereof | |
| CN117797056A (en) | Compound essential oil for improving skin state and skin care product composition containing compound essential oil | |
| CN103110534A (en) | Combined essence of composite velvet antler polypeptide lyophilized powder and nano-scale buffering microemulsion for skin beauty and health care and preparation method of combined essence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190920 |